Press Releases

AI tool helps find life-saving medicine for rare disease

Set to enter hospice care, a patient with idiopathic multicentric Castleman’s disease is now in remission after treatment with a medication predicated as the top treatment by an AI-guided analysis.

University of Pennsylvania's Dr. Melanie Mumau Presented with $20,000 Research Grant from Uplifting Athletes

Dr. Melanie Mumau is among 10 rare disease researchers to be awarded a grant at Uplifting Athletes’ Sixth Annual Young Investigator Draft presented by CSL Behring on Feb. 4 at Lincoln Financial Field.

CDCN Hosting Annual Fundraiser in its Quest for a Cure

Castleman Disease Colaborative Network to Host Annual Fundraiser in its Quest to Cure This Rare and Potentialy Fatal Disease.

New article published in the New England Journal of Medicine.

Penn Medicine Researchers Chart a Path Forward with Unifying Definition of Cytokine Storm.

Major study published uncovering mechanisms involved in Castleman disease

Penn Researchers Discover Key Mechanism of Cytokine Storm in Castleman Disease.

Taking Inventory of Which Drugs the World Is Using to Treat COVID-19

Penn researchers create database to categorize off-label use and look for promising leads.

Treatment Doctor Tested On Himself Can Put Others into Remission

Research identifies therapeutic target for Castleman disease patients resistant to approved therapy.

CDCN Partners with Janssen to Perform Proteomics Study

The Castleman Disease Collaborative Network announced a collaboration with Janssen Research & Development, LLC, to conduct a proteomics study of idiopathic multicentric Castleman disease (iMCD).

International Team Establishes First Diagnostic Criteria for Idiopathic Multicentric Castleman Disease

Criteria will help patients with the rare, immunological disorder receive more precise treatments faster.

FDA Approves Siltuximab for Castleman Disease

The U.S. Food and Drug Administration approved Sylvant (siltuximab) to treat patients with multicentric Castleman disease (MCD); siltuximab is the first-ever FDA-approved medication for CD.